Needham raised the firm’s price target on Heron Therapeutics to $5 from $4 and keeps a Buy rating on the shares. The analyst cites the company’s better than expected Q4 sales due to stronger upticks in Zynrelef, Cinvanti and Sustol. Heron’s strong finish to 2023 should increase confidence in the company’s ability to meet its top-line guidance of $138M-$158M and its Q4 target of positive EBITDA, the firm tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HRTX:
- Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
- Options Volatility and Implied Earnings Moves Today, March 12, 2024
- Heron Therapeutics Inc (HRTX) Q4 Earnings Cheat Sheet
- Biotech Alert: Searches spiking for these stocks today
- Heron Therapeutics Gains FDA Nod for ZYNRELEF® Expansion
